Neurological disorder biotech Trevi Therapeutics files for an $86 million IPO
Trevi Therapeutics, a clinical stage biotech developing therapies for neurological disorders, filed on Friday with the SEC to raise up to $86 million in an initial public offering.
The New Haven , CT-based company was founded in 2011 and plans to list on the Nasdaq under the symbol TRVI. Trevi Therapeutics filed confidentially on November 19, 2018. SVB Leerink, Stifel and BMO Capital Markets are the joint bookrunners on the deal. No pricing terms were disclosed.
The article Neurological disorder biotech Trevi Therapeutics files for an $86 million IPO originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.
Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital's Renaissance IPO ETF (symbol: IPO), Renaissance International ETF (symbol: IPOS), or separately managed institutional accounts may have investments in securities of companies mentioned.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.